BTMD logo

biote Corp. Stock Price

NasdaqGM:BTMD Community·US$76.4m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

BTMD Share Price Performance

US$2.25
-1.89 (-45.65%)
US$2.99
Fair Value
US$2.25
-1.89 (-45.65%)
24.6% undervalued intrinsic discount
US$2.99
Fair Value
Price US$2.25
AnalystConsensusTarget US$2.99
AnalystHighTarget US$4.00
AnalystLowTarget US$2.00

BTMD Community Narratives

·
Fair Value US$2.99 29.7% undervalued intrinsic discount

Commercial Reorganization And E-Commerce Expansion Will Drive Mixed Future Prospects

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
·
Fair Value US$4 47.5% undervalued intrinsic discount

Digital Health Expansion Will Elevate Preventative Care Despite Regulatory Hurdles

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$2 5.0% overvalued intrinsic discount

Regulatory Risks Will Limit Hormone Therapy But Telemedicine Will Help

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$2.99
29.7% undervalued intrinsic discount
Revenue
5.26% p.a.
Profit Margin
2.34%
Future PE
18.88x
Price in 2029
US$3.64

Trending Discussion

Updated Narratives

BTMD logo

BTMD: New Interim Leadership And 2026 Outlook Will Support Earnings Upside

Fair Value: US$2.99 29.7% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BTMD logo

BTMD: Recall And Investment Reset Will Support 2026 Revenue Recovery Potential

Fair Value: US$4 47.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BTMD logo

BTMD: Affordable Medicines Theme Will Support Upside As 2026 Plan Advances

Fair Value: US$2 5.0% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with slight risk.

4 Risks
2 Rewards

biote Corp. Key Details

US$188.2m

Revenue

US$56.2m

Cost of Revenue

US$131.9m

Gross Profit

US$116.3m

Other Expenses

US$15.6m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.51
70.12%
8.29%
-220.4%
View Full Analysis

About BTMD

Founded
2012
Employees
223
CEO
Robert Peterson
WebsiteView website
www.biote.com

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.

Recent BTMD News & Updates

Narrative Update Jun 22

BTMD: New Interim Leadership And 2026 Outlook Will Support Earnings Upside

Analysts have trimmed their price target on biote by $1, citing updated assumptions around discount rates and forward P/E, while keeping fair value and long term growth expectations broadly in line with prior views. What's in the News for biote biote reaffirmed full year 2026 earnings guidance, maintaining an outlook for revenue above $190 million.
Narrative Update Jun 05

BTMD: Recall Resolution And Higher Spending Will Support Later Earnings Upside

Narrative Update: Biote Analysts have trimmed their average price targets for Biote by around $1, reflecting recent research that points to mixed signals from Q4 results, a lower FY26 outlook after the voluntary recall and higher investment plans, as well as progress on sales force and platform initiatives that could support improved profitability and a lower future P/E assumption. Analyst Commentary Recent research highlights a mix of optimism and caution around Biote, with analysts adjusting price targets lower in response to Q4 results, updated FY26 guidance and ongoing investment plans.

Recent updates

No updates